Vivos Inc (RDGL)

$0.05 0.00 (-3.91%)
Market Cap 28.35M
Revenue (ttm) 70,000.00
Net Income (ttm) -3.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,385.71%
Debt to Equity Ratio 0.00
Volume 793,962
Avg Vol 1,702,332
Day's Range N/A - N/A
Shares Out 493.96M
Stochastic %K 70%
Beta -0.73
Analysts Strong Buy
Price Target N/A

Company Profile

Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel po...

Industry: Medical Devices
Sector: Healthcare
Phone: 509 222 2222
Address:
1030 N Center Parkway, Suite N288, Kennewick, United States
UpsideTheory
UpsideTheory Aug. 19 at 5:51 PM
$RDGL what a steal this is right now, cant believe it
2 · Reply
PopeyeTheTrader
PopeyeTheTrader Aug. 19 at 5:18 PM
$RDGL Moderna $MRNA Merck announced positive interim results from their Phase 3 INTerpath-001 trial of the personalized mRNA cancer vaccine intismeran autogene (also called mRNA-4157) combined with Merck’s Keytruda (pembrolizumab) for high-risk melanoma. Key details • The trial enrolled 1,137 patients with completely resected (surgically removed) stage IIB–IV melanoma. • Patients received either the combination (personalized vaccine + Keytruda, up to nine doses over about a year) or Keytruda alone. • Interim results showed the combination met its primary endpoint of improving recurrence-free survival (RFS) and its secondary endpoint of improving distant metastasis-free survival (DMFS) versus Keytruda alone. • No new safety signals were reported. • This is described as the first successful late-stage (Phase 3) randomized trial for an mRNA-based cancer vaccine / neoantigen therapy, and the first to show added benefit over Keytruda alone in this adjuvant melanoma setting
2 · Reply
Fireballmillionaire
Fireballmillionaire Aug. 19 at 2:24 AM
$RDGL I really like the recent news.. Unfortunately very slow process.. But if you look at it, there's big money on the line.. most longs are deep in the red... great spot for new people to buy in!! Even the top dogs (ceo) have been buying at these levels.. just be prepared to hold for a few years.. I am going on 6...
3 · Reply
Rogggggg
Rogggggg Aug. 18 at 8:30 PM
$RDGL not understanding the need for a manufacturing facility for a treatment that isn’t approved for humans and the barrier for expanding isopet isn’t a shortage of product but a lack of customers… am I misunderstanding something?
3 · Reply
Seguro
Seguro Aug. 18 at 6:53 PM
$RDGL I'm delerious with the splinters of sunlight that the fudsters try to distort into convulsions of ignorance...lol Rdgl is on the path of huge success...
1 · Reply
Dumbdumb4ever
Dumbdumb4ever Aug. 18 at 4:03 PM
$RDGL the new release says they treated 12 patients in India now. Is this a typo???
1 · Reply
Doccjc62
Doccjc62 Aug. 18 at 1:15 PM
$RDGL You now have …. FDA IDE approved → manufacturing infrastructure established → IsoPet production/shipping underway → India manufacturing authorization → Mayo IRB next → first human patient.
2 · Reply
Doccjc62
Doccjc62 Aug. 18 at 12:54 PM
$RDGL https://www.benzinga.com/pressreleases/26/08/g61270510/vivos-inc-achieves-two-major-operational-milestones-first-isopet-shipments-new-u-s-production-facili
0 · Reply
Doccjc62
Doccjc62 Aug. 17 at 4:06 PM
$RDGL I believe we'll get IRB approval news this week or next week. After IRB approval, the first patient dosed PR won't be too far behind imo. and the results from the 5 patients could be by the end of this year. It is nice to have the IDE behind us and the Mayo Clinic human trials to look forward to.
1 · Reply
Rogggggg
Rogggggg Aug. 17 at 2:43 PM
$RDGL news?
2 · Reply
Latest News on RDGL
No data available.
UpsideTheory
UpsideTheory Aug. 19 at 5:51 PM
$RDGL what a steal this is right now, cant believe it
2 · Reply
PopeyeTheTrader
PopeyeTheTrader Aug. 19 at 5:18 PM
$RDGL Moderna $MRNA Merck announced positive interim results from their Phase 3 INTerpath-001 trial of the personalized mRNA cancer vaccine intismeran autogene (also called mRNA-4157) combined with Merck’s Keytruda (pembrolizumab) for high-risk melanoma. Key details • The trial enrolled 1,137 patients with completely resected (surgically removed) stage IIB–IV melanoma. • Patients received either the combination (personalized vaccine + Keytruda, up to nine doses over about a year) or Keytruda alone. • Interim results showed the combination met its primary endpoint of improving recurrence-free survival (RFS) and its secondary endpoint of improving distant metastasis-free survival (DMFS) versus Keytruda alone. • No new safety signals were reported. • This is described as the first successful late-stage (Phase 3) randomized trial for an mRNA-based cancer vaccine / neoantigen therapy, and the first to show added benefit over Keytruda alone in this adjuvant melanoma setting
2 · Reply
Fireballmillionaire
Fireballmillionaire Aug. 19 at 2:24 AM
$RDGL I really like the recent news.. Unfortunately very slow process.. But if you look at it, there's big money on the line.. most longs are deep in the red... great spot for new people to buy in!! Even the top dogs (ceo) have been buying at these levels.. just be prepared to hold for a few years.. I am going on 6...
3 · Reply
Rogggggg
Rogggggg Aug. 18 at 8:30 PM
$RDGL not understanding the need for a manufacturing facility for a treatment that isn’t approved for humans and the barrier for expanding isopet isn’t a shortage of product but a lack of customers… am I misunderstanding something?
3 · Reply
Seguro
Seguro Aug. 18 at 6:53 PM
$RDGL I'm delerious with the splinters of sunlight that the fudsters try to distort into convulsions of ignorance...lol Rdgl is on the path of huge success...
1 · Reply
Dumbdumb4ever
Dumbdumb4ever Aug. 18 at 4:03 PM
$RDGL the new release says they treated 12 patients in India now. Is this a typo???
1 · Reply
Doccjc62
Doccjc62 Aug. 18 at 1:15 PM
$RDGL You now have …. FDA IDE approved → manufacturing infrastructure established → IsoPet production/shipping underway → India manufacturing authorization → Mayo IRB next → first human patient.
2 · Reply
Doccjc62
Doccjc62 Aug. 18 at 12:54 PM
$RDGL https://www.benzinga.com/pressreleases/26/08/g61270510/vivos-inc-achieves-two-major-operational-milestones-first-isopet-shipments-new-u-s-production-facili
0 · Reply
Doccjc62
Doccjc62 Aug. 17 at 4:06 PM
$RDGL I believe we'll get IRB approval news this week or next week. After IRB approval, the first patient dosed PR won't be too far behind imo. and the results from the 5 patients could be by the end of this year. It is nice to have the IDE behind us and the Mayo Clinic human trials to look forward to.
1 · Reply
Rogggggg
Rogggggg Aug. 17 at 2:43 PM
$RDGL news?
2 · Reply
GIFking
GIFking Aug. 16 at 11:21 PM
$RDGL
0 · Reply
dk67
dk67 Aug. 13 at 6:39 PM
$RDGL 10Q is filed. As usual, nothing earth shattering. Isopet revenue is up, costs are down, but not yet profitable Management is being responsible with cash and dilution, which is a nice change for OTC. Despite the cheerleading by "$5 organically" there are no multi-million dollar licensing agreements yet. So we wait. https://www.sec.gov/ix?doc=/Archives/edgar/data/1449349/000149315226037380/form10-q.htm
4 · Reply
Richbagholderr
Richbagholderr Aug. 13 at 2:30 PM
$RDGL
0 · Reply
cp07451
cp07451 Aug. 13 at 2:22 PM
$RDGL The India Clinical Trial pause for audits doesn't help.
2 · Reply
Daybyday5
Daybyday5 Aug. 13 at 2:00 PM
$RDGL Brad continues buying: https://archive.fast-edgar.com/20260810/AO22N22MZ222R2D2222D22E2JLRDR2223282/
0 · Reply
Daybyday5
Daybyday5 Aug. 13 at 1:54 PM
$RDGL No offering sold this quarter... That's even worse than I thought....
0 · Reply
Daybyday5
Daybyday5 Aug. 13 at 1:51 PM
$RDGL 10-q is out: https://archive.fast-edgar.com/20260812/AM22T22CZW2RM2UZ2A2L2WY2APHG7Z22Z282/
1 · Reply
anderson800
anderson800 Aug. 13 at 12:17 PM
$RDGL a couple of highlights 142% increase in revenues from previous year's quarter In that same period total operating expenses decreased 20% That's a good sign that with more revenue expenses are decreasing. And of course I think we knew that they had been selling shares. In March and April they sold about 27 million shares for about 2.2 million dollars.
1 · Reply
anderson800
anderson800 Aug. 13 at 12:07 PM
$RDGL the new filing is out. Have not had a chance to delve into it yet: https://www.sec.gov/Archives/edgar/data/1449349/000149315226037380/0001493152-26-037380-index.htm
0 · Reply
Seguro
Seguro Aug. 12 at 11:19 PM
$RDGL https://search.brave.com/ask?q=when+is+rdgl+deadline+to+submit+for+mayo+Clinic+irb+review&conversation=096f57b6b15d30e44cf0f8301199efee035d#MwtnGCwnCyazFh2CDhuOSFPh-7WdRRvO35dOkUV6Y5A John Smith and team I'm sure will deliver the positive results
0 · Reply
Doccjc62
Doccjc62 Aug. 12 at 7:00 PM
$RDGL These prices won't last very much longer imo/. Upcoming IRB approval and first patient dosed is right around the corner. We could get results from the 5 patients in the Mayo clinic trial by the end of the year. We've seen what the treatment can do in animals(over 200 successful cases) and we had a sneak peak at what it can do in humans from the India studies. The science works. The share price will correct.
2 · Reply
AGINST_M
AGINST_M Aug. 12 at 5:18 PM
$RDGL https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177869218 Nice try from this pathetic poster and his ilk on ihub. Yo, before your very eyes, y'all will watch this company grow and become successful despite the strong hopes on your collective part for it to fail. There is a reason why all sorts of strange handles are popping up on RDGL msg boards; not a coincidence at all. Keep trying though but I for one already know your best efforts won't be enough. Whether it sits well with you or not, vivos and radiogel will prove their credibility and with that its investors will be handsomely rewarded. ONWARD VIVOS!
1 · Reply